* This work was supported, in whole or in part, by National Institutes of Health Grants HL and HL (to M. G. S.-T.). S
|
|
- Julian McCarthy
- 6 years ago
- Views:
Transcription
1 THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 285, NO. 46, pp , November 12, by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A. Apolipoprotein A-I Modulates Regulatory T Cells in Autoimmune LDLr /, ApoA-I / Mice * S Received for publication, May 1, 2010, and in revised form, August 18, 2010 Published, JBC Papers in Press, September 10, 2010, DOI /jbc.M Ashley J. Wilhelm 1, Manal Zabalawi, John S. Owen, Dharika Shah, Jason M. Grayson 2, Amy S. Major 3, Shaila Bhat, Dwayne P. Gibbs, Jr. 4, Michael J. Thomas 5, and Mary G. Sorci-Thomas 6 From the Department of Pathology, Lipid Sciences Research Center, and Department of Biochemistry, Microbiology, and Immunology, Wake Forest University School of Medicine, Winston-Salem, North Carolina and the Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee The immune system is complex, with multiple layers of regulation that serve to prevent the production of self-antigens. One layer of regulation involves regulatory T cells (Tregs) that play an essential role in maintaining peripheral self-tolerance. Patients with autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis have decreased levels of HDL, suggesting that apoa-i concentrations may be important in preventing autoimmunity and the loss of self-tolerance. In published studies, hypercholesterolemic mice lacking HDL apoa-i or LDLr /, apoa-i / (DKO), exhibit characteristics of autoimmunity in response to an atherogenic diet. This phenotype is characterized by enlarged cholesterol-enriched lymph nodes (LNs), as well as increased T cell activation, proliferation, and the production of autoantibodies in plasma. In this study, we investigated whether treatment of mice with lipid-free apoa-i could attenuate the autoimmune phenotype. To do this, DKO mice were first fed an atherogenic diet containing 0.1% cholesterol, 10% fat for 6 weeks, after which treatment with apoa-i was begun. Subcutaneous injections of 500 g of lipid-free apoa-i was administered every 48 h during the treatment phase. These and control mice were maintained for an additional 6 weeks on the diet. At the end of the 12-week study, DKO mice showed decreased numbers of LN immune cells, whereas Tregs were proportionately increased. Accompanying this increase in Tregs was a decrease in the percentage of effector/effector memory T cells. Furthermore, lipid accumulation in LN and skin was reduced. These results suggest that treatment with apoa-i reduces inflammation in DKO mice by augmenting the effectiveness of the LN Treg response. * This work was supported, in whole or in part, by National Institutes of Health Grants HL and HL (to M. G. S.-T.). S The on-line version of this article (available at contains supplemental Figs Supported by National Institutes of Health Training Grant T32HL from the NHLBI and in part by an American Heart Association predoctoral fellowship. 2 Supported by National Institutes of Health Grant A and American Cancer Society Research Scholar Grant RSG MBC. 3 Supported by National Institutes of Health Grant HL and The Lupus Research Institute, New York. 4 Supported by National Institutes of Health Training Grant SR25HL Supported by American Heart Association Grant 09GRNT To whom correspondence should be addressed: Dept. of Pathology, Section on Lipid Sciences, Wake Forest University School of Medicine, Medical Center Blvd., Winston-Salem, NC msthomas@wfubmc.edu. Increased concentrations of high density lipoprotein (HDL) apolipoprotein A-I (apoa-i) in plasma are a well established negative risk factor for coronary heart disease (1). ApoA-I is the major protein contained in HDL, and it is essential for its formation and function (2), as well as associated anti-inflammatory properties (3 5). Decreased concentrations of HDL apoa-i are associated not only with increased atherosclerosis but also with autoimmune disorders such as systemic lupus erythematosus and rheumatoid arthritis (6, 7). Although the effects of HDL on atherosclerosis have been widely reported, its effects on autoimmunity are not well understood. Recent studies from our laboratory indicate that in hypercholesterolemic mice lacking plasma apoa-i, an increased susceptibility to autoimmunity exists. The autoimmune phenotype is characterized by enlarged lymph nodes (LN), 7 cellular activation, proliferation, and lipid accumulation (8 10), Interestingly, the autoimmune phenotype appears to be triggered by a cholesterol-containing diet, likely because of the absence of HDL and the lack of apoa-i-facilitated cholesterol efflux (8, 10) via ABCA1. This raises the possibility that HDL apoa-i may be a common link between autoimmunity, inflammation, and atherosclerosis. Therefore, to test whether treatment with lipid-free apoa-i could attenuate ongoing inflammation, DKO mice were first fed an atherogenic diet containing 0.1% cholesterol, 10% fat for 6 weeks, after which treatment with apoa-i was begun. Subcutaneous injections of 500 g of lipid-free apoa-i was administered every 48 h during the treatment phase. These and control mice were maintained for an additional 6 weeks on diet. At the end of the 12-week study, DKO mice showed decreased numbers of LN immune cells, whereas Tregs were proportionately increased. Accompanying this increase in Treg cell number was a decrease in the percentage of effector/effector memory T cells as well as a reduction in the amount of lipid accumulation in LN and skin. Overall, these results suggest that treatment with apoa-i reduced inflammation and the accompanying autoimmune phenotype by restoring the effectiveness of the LN Treg response. EXPERIMENTAL PROCEDURES Mice, Diet, and Study Design LDLr /, apoa-i / (DKO), and LDLr / (SKO) mice were fully backcrossed into the 7 The abbreviations used are: LN, lymph node; Treg, regulatory T cell; DC, dendritic cell JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 285 NUMBER 46 NOVEMBER 12, 2010
2 C57BL/6 background (8 10). Mice were housed at the Wake Forest University Medical Center, and all procedures were approved by the Wake Forest University Medical Center Animal Care and Use Committee. Male mice from both genotypes were fed an atherogenic diet consisting of 0.1% cholesterol with 10% palm oil beginning at 6 weeks of age for a period of 12 weeks (8 10). As controls, mice of each genotype were fed a Purina chow diet for the same length of time. All mice were maintained in a temperature-controlled room with a 12-h light/ 12-h dark cycle. Mice were fasted for 3 h prior to being anesthetized for blood collection by cardiac puncture and subsequent blood processing (8 10). All mice used were males unless otherwise noted. In studies designed to test the effects of apoa-i treatment on established diet-induced inflammation, age-matched male DKO and SKO mice were fed an atherogenic diet for 6 weeks before beginning 6 weeks of treatment with lipid-free human apoa-i while still consuming the atherogenic diet. During the treatment period, mice were subcutaneously injected with 500 g of lipid-free human apoa-i every 48 h. As controls, DKO and SKO mice were fed as described above but were subcutaneously injected with 500 g of bovine serum albumin every 48 h. Some mice were sacrificed after 6 weeks of diet consumption before beginning the treatment phase of the study for comparison. Purification of Human Plasma ApoA-I and ELISA Wildtype human apoa-i was purified by adjusting the equivalent of 1 unit of human plasma with KBr to d g/ml and isolating the total lipoprotein fraction via ultracentrifugation for 18 h at 50,000 rpm, 15 C, in a Ti 50.1 rotor. To prevent methionine oxidation, hydrosulfite was maintained at a 10 M concentration at all centrifugation steps. The d fraction was then sequentially ultracentrifuged (Ti 50.1 rotor, 18 h, 15 C, 50,000 rpm) to remove VLDL and finally LDL to obtain the d g/ml fraction. The d g/ml fraction was centrifuged again at d g/ml to remove any traces of albumin. The d g/ml fraction was then dialyzed again against 10 mm ammonium bicarbonate, ph 7.4, and then lyophilized. The dried pellet consisting of both apoa-i and apoa-ii was solubilized with 50 ml of 6 M guanidine hydrochloride and then exhaustively dialyzed against 10 mm ammonium bicarbonate, ph 7.4. The denatured HDL was ultracentrifuged at d g/ml for 18 h, 15 C, in a Ti 50.1 rotor (11). The d g/ml fraction was taken and exhaustively dialyzed against 10 mm ammonium bicarbonate, ph 7.4, and then lyophilized to dryness. The pellet was taken up in 40 ml of 6 M guanidine hydrochloride dialyzed against 10 mm ammonium bicarbonate, ph 7.4, and the apoprotein was allowed to refold. Following dialysis, protein concentration was determined, and the purity was verified by mass spectrometry (12). Both the concentrated BSA and apoa-i (4 5 mg/ml) were filtered through a m SpinX column (Costar) prior to subcutaneous injection. The human apoa-i concentration in plasma samples from mice bled at timed intervals following injection of apoa-i or BSA was determined by ELISA, as described previously (13, 14). Lipoprotein Separation and Characterization The lipoprotein cholesterol distribution was determined following fast protein liquid chromatography (FPLC) as described liter EDTA, ph 7.4, and 1.5 mmol/liter NaN 3. Approximately l fractions were collected, and 100 l from each fraction was used for cholesterol determination (13). To assess the human apoa-i distribution, 20 l from each fraction was separated on a 12% SDS-PAGE Western blot performed for human apoa-i, as described previously (13). To assess the rate of apoa-i lipidation following subcutaneous injection, timed plasma samples were taken, and Western blot was performed. Plasma samples were separated by 4 30% nondenaturing gradient gel electrophoresis (15 17) by running at 2800 V/h. Following electrophoresis, the gel was blotted onto a PVDF membrane (Whatman) at 23 V, overnight at 4 C. Following transfer, the membrane was fixed in 10% acetic acid for 15 min and then air-dried for 15 min. The membrane was then incubated in 50 mm Tris-HCl, ph 8.0, 80 mm NaCl 2,2mMCaCl 2, containing 5% nonfat dry milk and 0.2% Nonidet P-40 for 30 min. After the blocking step, the membrane was incubated with a 1:1000 dilution of goat anti-human apoa-i (Chemicon) for 1 h and then washed and incubated with a 1:3000 dilution of HRP-conjugated donkey anti-goat IgG for 1 h. The membrane was finally washed with Tris-saline, MgCl 2, ph 9.6, before incubating with the Pierce SuperSignal West Pico chemiluminescent substrate. The chemiluminescence was visualized by an LSA-3000 imaging system (Fujifilm Life Science). Particle size was determined by comparison to protein standards of known Stokes radius (16, 17). Mass Spectrometry of Cellular Lipids For the determination of free and esterified cholesterol, tissue and cells were extracted using chloroform/methanol (2:1) as described previously (8 10). Cholesterol, together with other neutral lipids, was isolated from the lipid extract using a modification of the method of Kaluzny et al. (18) and analyzed by mass spectrometry as described previously (10). Cholesterol Efflux Studies Lymph nodes were collected and placed in serum-free RPMI 1640 medium, and cells were isolated as described previously (10, 19, 20). Once a single cell suspension was obtained, cells were added to each well of a 6-well plate, and the volume was adjusted to 1 ml with OpTmizer T cell expansion SFM (Invitrogen). 125 I-Labeled human apoa-i was added as an acceptor for the efflux of lymphocyte lipids to a final concentration of 150 g/ml and incubated overnight at 37 C in a CO 2 incubator. Approximately 24 h later, the medium was collected, dialyzed, and then concentrated before injection onto FPLC, as described previously for the isolation of ABCA1-derived nascent HDL (21). Following separation, each fraction was subjected to scintillation counting for 3 H content and run on 4 30% nondenaturing gradient gels for particle sizing (15 17). [ 3 H]Thymidine Proliferation Assay Lymph nodes and spleens were collected and placed in serum-free RPMI 1640 medium, and cells were isolated as described previously (10, 19, 20). Once a single cell suspension was obtained, cells were added to each well of a 24-well plate, and the volume was adjusted to 0.5 ml with OpTmizer T cell expansion SFM (Invitrogen). Half the wells were stimulated with a mixture of anti-cd3 and anti-cd28 (BD Biosciences) containing 1 g/ l NOVEMBER 12, 2010 VOLUME 285 NUMBER 46 JOURNAL OF BIOLOGICAL CHEMISTRY 36159
3 of each at the final concentration. The cells were incubated at 37 C in a CO 2 incubator for 24 h after which time 1 Ci of [ 3 H]thymidine was added to each well, and the cells were incubated for an additional 24 h. To determine the amount of incorporated [ 3 H]thymidine, cold TCA was added to each well to adjust to a final concentration of 3%, and the mixture was filtered through glass fiber filters. The filters were thoroughly washed and then dried and subjected to scintillation counting. Histology Freshly isolated tissue was collected and embedded into OCT from which m-thick sections were prepared using a Leica cryostat at 20 C. Sections were stained with Oil Red O and counterstained with Mayer s hematoxylin as described previously (8, 10) or stained with hematoxylin and eosin (9). Immunofluorescence Microscopy Fresh tissue was embedded into OCT and then m sections were obtained. Dried acetone-fixed sections were first incubated in a solution consisting of 1% normal goat serum and 1% BSA in PBS for 1 h at room temperature. Then sections were incubated with purified rat anti-mouse CD68 (AbD Serotec) or CD11c hamster anti-mouse (Pharmingen) at a 1:100 dilution or goat antimouse IgG (Jackson ImmunoResearch) at a 1:200 dilution for 30 min at room temperature and then briefly washed in PBS. Next, sections were incubated in their respective secondary antibody goat anti-rat IgG CD68 Cy3 (Rockland) at 1:300 or biotin-conjugated CD3e, CD11c mouse anti-hamster IgG (Pharmingen) for 45 min at room temperature. After washing in PBS, slides used for the detection of CD11c were incubated in Vectastain ABC-AP reagent from the Vectastain ABC-AP standard kit (Vector Laboratories) for 30 min. Vector Red (Vector Laboratories) was used as a substrate according to the manufacturer s protocol. Finally, sections were washed in PBS and then counterstained with DAPI for 5 min before being mounted with Fluorogel mounting media (Electron Microscopy Sciences). Immunofluorescence was visualized using a Nikon Eclipse TE2000-S microscope. For all staining, at least four sections per animal, with a minimum of five mice per group, were analyzed. Cell Isolation and Surface Staining LNs, including the brachial, axillary, inguinal, and superficial cervical subsets, were collected and placed in RPMI 1640 medium. Cells were isolated as described previously (10, 19, 20). Antibodies including antimouse CD3, CD4, CD8, CD62L, CD11c, CD11b, CD69, and CD44 were obtained from BD Biosciences. Rat anti-mouse F4/80 was obtained from ebiosciences. Surface staining was performed as described previously (10, 20). Tregs were stained using the mouse regulatory T cell staining kit (ebioscience) according to the manufacturer s instructions. Briefly, cells were stained with rat anti-mouse CD4 and CD25 antibodies for 30 min at 4 C to measure these surface molecules. Cells were then washed and resuspended in a permeabilization solution for 30 min at 4 C. Cells were again washed and incubated in 1 g of Fc block for 15 min. Next, 0.5 g of rat anti-mouse FoxP3, an intracellular stain, was added to each sample and incubated for 30 min at 4 C. A mouse IgG isotype control (ebioscience) was used in each assay to subtract background fluorescence. Finally, samples were washed and resuspended in 2% paraformaldehyde in PBS before acquisition of samples using a FACSCalibur (BD Biosciences). Analysis of Immune Cell Population Data Data were analyzed using FlowJo software (TreeStar, San Francisco, CA). Cell populations measured included effector memory phenotype T cells (CD4 CD62L low, CD8 CD62L low, CD4 CD44 high, and CD8 CD44 high ), activated T cells (CD4 CD69 high and CD8 - CD69HIGH), Treg (CD4 CD25 FoxP3 ), DCs (CD3 CD11c and CD3 CD11b CD11c ), and macrophages (CD11c - CD11b F4/80 ). The total number of cells staining positive for a particular set of stains was calculated based on the total number of LN cells in four subsets of skin draining LNs and the percent of those cells staining positive for each condition, as described previously (10). Populations were also expressed as the percent of the total number of LN cells such as DCs and macrophages or as the percent of total CD4 or CD8 cells as in the case of effector/ effector memory T cells, activated T cells, and Tregs. Measurement of Plasma Antibodies Plasma anti-dsdna and oxldl antibodies were measured by ELISA, as described previously (22 25). Briefly, plates were coated with specific antigen and blocked in 1% BSA/PBS for 2 h at room temperature. Mouse serum was added at a dilution between 1:500 and 1:5000 and incubated overnight at 4 C. Plates were washed with 0.5% Tween 20/PBS (PBS-T) and incubated with biotinconjugated goat anti-mouse Ig(H L) (Southern Biotech, Birmingham, AL) for 45 min at room temperature and then incubated with avidin-peroxidase for 30 min at room temperature. Plates were then washed with PBS-T and developed using tetramethylbenzidine substrate (BD Biosciences). Anti-oxidized immunoglobulin isotype ELISAs were performed as described above using a biotin-conjugated goat anti-mouse IgG1, IgG2c, or IgM (Southern Biotech) secondary antibody. RESULTS Study Design and Treatment with Lipid-free Human ApoA-I Studies were carried out to determine whether treatment with lipid-free human apoa-i could attenuate the autoimmune phenotype in diet-fed DKO (LDLr /, apoa-i / ) mice. The design of the study is shown in Fig. 1, panel A. All male DKO mice were first fed an atherogenic diet containing 0.1% cholesterol, 10% fat for 6 weeks, after which one-half of the mice received subcutaneous injections of 500 g of apoa-i every 48 h and are designated DKO A-I. The second half of the DKO mice received 500 g of BSA every 48 h, designated DKO BSA. All mice were maintained for an additional 6 weeks on the diet during the treatment period for a total of 12 weeks of diet. Additional control mice, SKO (LDLr / ) were also treated in a similar fashion with either apoa-i or BSA treatment. Fig. 1, panel B, shows that 7 8 h post-lipid-free apoa-i injection, plasma levels reached a peak concentration of 4 mg/dl, suggesting that injection every 48 h would maintain low levels of plasma apoa-i. Separation of terminal DKO plasma into lipoprotein fractions, Fig. 1, panel C, using FPLC suggests that treatment with either apoa-i or BSA had little effect on the overall HDL cholesterol levels because both DKO AI (closed circle) and DKO BSA (open diamond) showed no discernable HDL-sized cholesterol peak, which was easily observed after separation of SKO mouse plasma (Fig. 1, panel C, shaded JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 285 NUMBER 46 NOVEMBER 12, 2010
4 FIGURE 1. Study design for apoa-i treatment. Panel A, study design shows 6 7-week-old mice were fed an atherogenic diet for 6 weeks before beginning 6 weeks of subcutaneous injections of 500 g of lipid-free human apoa-i or BSA every 48 h while maintained on the atherogenic diet for a total of 12 weeks; panel B, timed plasma samples were assayed for human apoa-i following injection of lipid-free apoa-i; panel C, lipoprotein cholesterol distribution following FPLC of mouse plasma; panel D, Western blot of 4 30% nondenaturing gradient gel of timed plasma samples following injection of lipid-free human apoa-i. LDLr /, apoa-i / DKO mice and LDLr / SKO mice. All data represent a minimum of 5 8 male mice per group. squares). However, Western blot analysis on individual FPLC fractions corresponding to HDL-sized particles indicated the presence of human apoa-i in fractions from DKO A-I mice but not from DKO BSA mice. Further studies were conducted to determine the rate of apoa-i lipidation following injection. Western blot analysis was performed on post-injection plasma samples following 4 30% nondenaturing gradient gel electrophoresis, as shown in Fig. 1, panel D. Results confirmed the presence of small HDL-sized particles in DKO A-I mice but not DKO BSA. Particle enlargement appeared to begin as early as 4 h post-injection, with particle size increasing up to 24 h post-injection. ApoA-I Treatment and Cellular LN Lipid Content In response to the atherogenic diet, both DKO and SKO mice display an expansion in the number of LN cells. Although DKO mice typically show a 6-fold expansion when compared with chow-fed DKO mice, SKO mice show only a 2-fold increase over chow-fed counterparts (10). Fig. 2, panel A, shows that the diet-induced LN cellular expansion appears to be progressive, because at 6 weeks after initiating the diet both genotypes of mice show a significant increase over their chow-fed counterparts. However, when the cellular content of DKO A-I LNs was examined, they showed a significant reduction compared with 12-week DKO mice but similar to the 6-week DKO mice. These results suggest that apoa-i treatment prevented any further increase in LN cell expansion but was not sufficient to bring LN cellularity back to levels seen in chow-fed mice during the course of this study. In addition to increases in LN cells, previous studies have shown that cellular expansion is also accompanied by an increase in LN cholesterol content, specifically for DCs, B, and T cells (10), which make up the majority of LN cells. Similar to previous studies, DKO mice had 2.5-fold more cellular cholesterol than SKO mice. Consistent with our hypothesis, the LN cells isolated from DKO A-I mice showed a significant decrease in their total cholesterol, as shown in Fig. 2, panel B, which was not statistically different from SKO levels. The decrease in total LN cell cholesterol in DKO AI mice appears to occur mainly through a reduction in free cholesterol, shown in Fig. 2, panel C, and although this appeared to be slightly higher, it was not statistically different from SKO levels. The ester cholesterol, Fig. 2, panel D, appeared to be slightly lower than DKO levels but did not reach statistical significance, again suggesting that apoa-i treatment attenuated cellular cholesterol accumulation but was not sufficient to bring sterol content completely back to SKO levels. To demonstrate that cholesterol-loaded immune cells can efflux lipids, 125 I-labeled apoa-i was added to the serum-free culture medium of freshly isolated LN cells obtained from 12-week DKO and SKO mice. Shown in supplemental Fig. 1, immune cells isolated from 12-week diet-fed DKO mice produced a greater amount of lipidated apoa-i particles that NOVEMBER 12, 2010 VOLUME 285 NUMBER 46 JOURNAL OF BIOLOGICAL CHEMISTRY 36161
5 FIGURE 2. Effects of apoa-i treatment on lymph node cell expansion and cholesterol content. Panel A shows the total number of cells isolated from four sets of skin draining LNs that include the brachial, inguinal, axillary, and superficial cervical subsets per mouse. Panels B D show the total cholesterol (TC), free cholesterol (FC), and esterified cholesterol (EC), respectively. LDLr /, apoa-i / DKO mice and LDLr / SKO mice. Mice were fed an atherogenic diet for 6 weeks before beginning 6 weeks of subcutaneous injections of 500 g of lipid-free human apoa-i (shown as DKO A-I) or BSA (shown as DKO and SKO) every 48 h while being maintained on the atherogenic diet for a total of 12 weeks. Data represent mean S.D. for n 5 15 mice per group. Different lowercase letters indicate significant differences at p FIGURE 3. Alterations in lymph node macrophage and dendritic cell populations following apoa-i treatment. Panels A and B show the number and percent of DCs in total LN cells, respectively. Panels C and D show the total number and percent of macrophages in total LN cells, respectively. LN cells were stained with CD3, CD11c CD11b, and F4/80 surface markers, and the CD3 CD11c population was measured for DCs and CD11c CD11b F4/80 population was measured for macrophages. All cell populations were determined by FACS. Total LN cells were isolated from four sets of skin draining LNs that include the brachial, inguinal, axillary, and superficial cervical subsets per mouse. Data represent mean S.D. for a minimum of n 5 14 mice per group. Different lowercase letters indicate significant differences at p ranged between 8.5 and 7.5 nm in diameter when compared with the amount of particles generated from SKO LN immune cells. Therefore, because lymphocytes from diet-fed DKO mice contain a greater mass of cholesterol than SKO lymphocytes (Fig. 2), it follows that they are more likely to efflux more cholesterol creating more lipidated particles once an acceptor, such as apoa-i, is available. Redistribution of Lymph Node Cell Populations We next examined whether apoa-i treatment would alter the distribution of specific subsets of LN immune cells. As we have shown in Fig. 2, and in previous studies (10), that DKO LNs increase in size, as well as in the total number of cells in response to diet, we next examined how apoa-i administration might alter the distribution of LN cell subsets. Fig. 3, panels A and C, shows the total number of LN DCs and macrophages, and Fig. 3, panels B and D, shows their percent distribution among all LN cells, respectively. As expected, both DKO and SKO mice have significantly increased numbers of DC after 6 and 12 weeks in response to the cholesterol- containing diet, shown in Fig. 3, panel A. However, the DKO AI group showed significantly more LN DCs when compared with 12-week DKO mice. An increase in DC cell number translated to an enrichment in the percent of DCs in LN cells, with apoa-i-treated DKO mice showing a slight enhancement over 6- and 12-week DKO mice, as shown in Fig. 3, panel B. Also expected, the number of LN macrophages was increased in response to both 6 and 12 weeks of diet, as seen previously (10). A small but not statistically significant decrease in the number of macrophages was seen between DKO mice that received apoa-i treatment and DKO mice that did not, as shown in Fig. 3, panel C. Despite the increase in total LN macrophages, the percent of macrophages in total LN cells was actually lower than in chow-fed mice, as shown in Fig. 3, panel D. Interestingly, apoa-itreated DKO mice showed a modest but significant increase in the percent of LN macrophage content over nontreated DKO mice, as shown in Fig. 3, panel D, but did not reach levels seen in chow-fed mice. Overall, these data suggest that diet increases LN macrophage as well as DC cell numbers regardless of the genotype. In addition, apoa-i treatment appears to have increased both DC and macrophage cell num JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 285 NUMBER 46 NOVEMBER 12, 2010
6 ApoA-I Modulates Inflammation and Lipid Accumulation oxldl total IgM isotype were unchanged, as shown in supplemental Fig. 3, panel B, among all treatment groups. The total IgG isotype of anti-oxldl was increased significantly in mice receiving apoa-i injections as compared with mice injected with BSA, which were similar to mice that did not receive any injections, shown in supplemental Fig. 3, panel C. Although there was a change in the total IgG isotype titer for anti-oxldl, there was no significant difference in the ratio of IgG1 to IgG2c isotypes for oxldl, among the different groups, as shown in supplemental Fig. 3, panel D. Induction of T-regulatory Cells Within the T cell subtypes, we also examined regulatory T cells or Tregs that are CD4 CD25 Foxp3. Both the number and percent distribution of CD4 CD25 FoxP3 cells are shown in Fig. 4, panels A C, respectively. Interestingly, after treatment with apoa-i, the number of LN CD4 CD25 FoxP3 cells was similar to levels seen in 6-week DKO mice (Fig. 4, panel A), whereas FIGURE 4. ApoA-I treatment attenuates LN regulatory T cell and effector/effector-memory populations. Panels A and B show the total number of LN cells staining for CD4 CD25 FoxP3 or the percent of the total 12-week diet DKO mice showed a CD4 cells, respectively. Panel C, left, shows representative dot plots for CD4 CD25 gate drawn off viable large increase compared with cells; panel C, right, for CD25 FoxP3 cells, showing DKO A-I (top), DKO BSA (middle), an, SKO BSA 12-week SKO mice. However, the (bottom) mice. Panel D shows total number of cells staining positive for CD4 CD62Llow effector/memory T cells. Panel E show the ratio of Treg to Teff (CD4 CD25 FoxP3 ) cells. Data represent mean S.D. for a minimum of distributions of Tregs expressed as n 6 8 mice per group. Different lowercase letters indicate significant differences at p the percentage of total CD4 cells, shown in Fig. 4, panels B and C, were bers in LN as well as their relative proportion among immune significantly increased in DKO AI mice when compared with cells. either 6- or 12-week DKO, suggesting that apoa-i treatment Reduction in Activated T Cell Populations We next exam- induced conditions favoring Treg cell expansion within the ined levels of T cells, which are one of the largest population of CD4 T cell pool. cells found in the LN. Striking effects of apoa-i treatment were As shown in previous studies (10), diet-fed DKO mice disseen on lymph node T cell isotypes, as shown in supplemental played a significant increase in different types of activated T Fig. 2. The supplemental Fig. 2, panel A, shows that a large cells. Activation markers such as CD69 and CD44 and low significant effect was observed in the number of CD4 expression of CD62L typify the DKO response to dietary chocd69high T cells in mice treated with apoa-i. This was accom- lesterol, which is not observed in diet-fed SKO mice (10). It then panied by a significant reduction in the percent of activated T seems logical to determine whether the increase in Tregs was cells as total CD4 cells, as shown in supplemental Fig. 2, panel associated with changes in the activation state of T cells in B when compared with untreated diet-fed DKO mice. Other apoa-i-treated DKO mice. In Fig. 4, panel D, the number of subtypes of activated T cells examined, such as CD8 CD69high CD4 CD62Llow effector/effector-memory T cells was reduced and CD8 CD62Llow, were also reduced in DKO A-I treated 2-fold in DKO A-I mice compared with DKO 12-week mice, mice when compared with untreated DKO mice (data not although not completely back to levels seen in SKO mice. shown). However, despite the dramatic changes in activated T Interestingly, when the ratio of Treg cells to total CD4 cells, cells populations in response to apoa-i treatment, there were or Teff cells was examined, as shown in Fig. 4, panel E, a small minimal to no reductions in autoantibody titers to dsdna, as decrease was seen in both diet-fed DKO and SKO mice in shown in supplemental Fig. 3, panel A, when compared with response to diet. However, DKO A-I mice showed an untreated DKO mice. This outcome is not unexpected because increase in the Treg/Teff ratio, suggesting that apoa-i treatautoantibody titers have been shown to turn over slowly in ani- ment may modulate T cell activation through an increase in mal models of autoimmunity (26). Additionally, titers to anti- Treg populations. NOVEMBER 12, 2010 VOLUME 285 NUMBER 46 JOURNAL OF BIOLOGICAL CHEMISTRY 36163
7 FIGURE 5. ApoA-I treatment modulates T cell response to stimulation. Panels A C show the percent [ 3 H]thymidine incorporation within immune cells isolated from lymph nodes and panels D F from spleen. Panels A and D show incorporation of [ 3 H]thymidine in unstimulated cells; panels B and E show incorporation of [ 3 H]thymidine in cells stimulated with anti-cd3 and CD28 for 24 h. Panels C and F shows the relative fold increase in response to stimulation (Stim). Data represent means S.D. for cells obtained from n 3 6 mice per treatment group. Different lowercase letters indicate significant differences at p T Cell Stimulation and Proliferation In view of the increase in the population of regulatory T cells within LNs of apoa-itreated DKO mice, we sought to determine whether the T cell response had been restored by apoa-i treatment. Ideally, if Treg function was restored, then T cell activation would be expected to be suppressed following apoa-i treatment, and the magnitude of [ 3 H]thymidine incorporation was lower than the chronically stimulated T cells from untreated DKO mice. Fig. 5 shows the percent [ 3 H]thymidine incorporation for LN-derived immune cells shown in panels A C and for spleen cells in panels D F under the following conditions: Fig. 5, panels A and D, unstimulated cells; panels B and E, stimulated cells, and panels C and F, the relative fold increase upon stimulation. Therefore, when T cells are stimulated with anti-cd3/cd28, the extent of [ 3 H]thymidine incorporation monitoring proliferation is greater in DKO apoa-i-treated cells when compared with T cells that have been chronically activated in the absence of apoa-i (Fig. 5, panel C). Skin Lipid Levels Normalized with ApoA-I Treatment The hallmark of the autoimmune phenotype in diet-fed DKO mice is the accumulation of cholesterol and inflammatory cells within the skin. Therefore, we sought to determine the effects of apoa-i treatment on this tissue. Both the skin total cholesterol (Fig. 6, panel A) and triglyceride content (Fig. 6, panel B) were measured as a function of time on the diet. As seen in Fig. 6, panel A, DKO skin cholesterol increased with time on the diet but not in SKO mice. After 6 weeks on the diet, DKO mice had 10 mg/g cholesterol in the skin, and by 12 weeks this doubled to 20 mg/g. Not only did apoa-i treatment prevent any further accumulation of cholesterol in the skin, but it actually reduced skin cholesterol levels to those seen in 4-week dietfed DKO mice, suggesting that further apoa-i treatment might have reduced it to levels seen in chow-fed mice. Unlike cholesterol, the triglyceride content of DKO and SKO mice skin differed 2-fold after only 2 weeks on the diet, as shown in Fig. 6, panel B. Interestingly, the diet-fed DKO skin triglycerides actually dropped with time on diet, whereas SKO mice showed a modest increase after 6 weeks on the diet. By 12-week DKO, skin triglyceride had dropped to only 25% of its original value. Unexpectedly mice treated with apoa-i showed skin triglyceride levels similar to 12-week SKO mice. Lipid changes were also seen at the histological level. Fig. 6, panel C, shows the results of Oil Red O staining of skin sections from each of the four different study groups. No differences were seen in skin morphology between DKO and SKO mice before 6 weeks of diet consumption (data not shown). By 6 weeks, thickening of the skin and small lipid droplets were apparent, with a reduction in the size and appearance of the skin fat layer. After 12 weeks of diet, DKO skin showed increased thickening and intense lipid staining in the dermis with an apparent loss of its fat layer. Quite dramatically, the apoa-i treatment group showed normalization in skin morphology and appeared similar to that seen in 6-week diet-fed DKO mice. Because tissue damage in certain autoimmune disorders has been associated with the presence of autoantibodies (27), we examined skin sections from each of the diet-fed groups for the presence of IgG. The supplemental Fig. 4, panels A C, shows that skin sections from diet-fed DKO mice (supplemental Fig. 4, panel B) contain the greatest deposit of IgG when compared JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 285 NUMBER 46 NOVEMBER 12, 2010
8 ApoA-I Modulates Inflammation and Lipid Accumulation FIGURE 6. ApoA-I treatment restores skin neutral lipid content. Panel A shows total skin cholesterol content expressed as mg/g wet weight. Panel B shows the total skin triglyceride content expressed as mg/g wet weight. Data represent mean S.D. for a minimum of n 5 8 mice per group. Different lowercase letters indicate significant differences at p Panel C shows Oil Red O staining of 10- m-thick skin sections from DKO 12-week chow-fed mice; DKO 6-week diet-fed mice; DKO 12-week diet-fed mice; DKO 12-week diet-fed mice 6-week apoa-i treatment. Sections shown are representative of at least four sections per animal with at least 4 6 different animals per genotype and treatment group. There were no regional skin staining differences observed among any of the genotypes or treatment groups. with either SKO (supplemental Fig. 4, panel A) or DKO mice treated with apoa-i (supplemental Fig. 4, panel C). These results strongly suggest that IgG or IgG-containing complexes represent a major contributor to skin inflammation in diet-fed DKO mice, because tissue damage in autoimmune disorders have been associated with the presence of autoantibody (27). Infiltration of Immune Cells Is Reversed after ApoA-I Treatment Further investigations into DKO skin morphology were carried out to characterize immune cell infiltration before and after apoa-i treatment. Fig. 7, panels A D, show H&E staining of representative skin sections from each of the four study groups. Fig. 7, panels E L, shows immunofluorescence detection of CD68 cells (panels E H) and CD11c cells (panels I L) for mice from each of the four study groups. From these data, we see that both CD68 as well as CD11c cells are present in the skin of diet-fed DKO after 6 weeks of diet, and their infiltration into the skin only increased with time on diet. Treatment of 6-week diet-fed DKO mice with apoa-i appears NOVEMBER 12, 2010 VOLUME 285 NUMBER 46 to have attenuated the infiltration of these immune cells and restored normal skin morphology. DISCUSSION This study demonstrates that the administration of lipid-free human apoa-i reduces inflammation and cholesterol accumulation in the skin and skin-draining LN of diet-fed male DKO mice. These conclusions were based on the findings that subcutaneous injections of apoa-i decreased cholesterol accumulation as well as the activation state of immune cells in LNs. In addition, in response to apoa-i treatment, there was a large decrease in skin cholesterol and an increase in triglyceride content accompanied by decreased cellularity and the restoration of skin architecture, morphology, and composition. Most importantly, a significant increase in the LN Tregs population was associated with a decrease in LN effector/effector-memory cells and an improved Treg/Teff ratio as well as a reduction in the activation state and proliferative response of the T cells. JOURNAL OF BIOLOGICAL CHEMISTRY 36165
9 ApoA-I Modulates Inflammation and Lipid Accumulation tion (29, 32). Thus, targeting of pathways to inhibit the inflammatory response is a potential therapeutic approach that may result in improved Treg function (29). It is important, however, to maintain a balance between Treg and effector cells because, although a deficiency of Tregs can result in severe autoimmune disease (33 35), it is possible that increased numbers of Tregs could negatively affect the immune response to infection (33). Previous studies from our laboratory indicate that the lack of cholesterol efflux in DKO mice was responsible for inflammation in the skin and LNs and the autoimmune phenotype (8 10). Importantly, inflammation and autoimmunity are induced by dietary cholesterol and can be fatal for as early as 12 weeks after beginning the diet (8 10). It is well accepted that HDL apoa-i has beneficial effects on atherosclerosis (1, 36 39), with both human and animal studies demonstrating that infusion of apoa-i or reconstituted HDL reduces atherosclerosis and vascular inflammation (40 44). D-4F, an apoa-i mimetic peptide, when administered in combination with pravastatin (45), was shown to inhibit collagen-induced arthritis, an animal model of rheufigure 7. ApoA-I treatment reduces immune cell infiltrate into the skin. Panels A D show H&E staining of matoid arthritis. While further skin sections from each of the four study groups; panels E H show immunofluorescence staining for CD68 studies with the 4F peptide showed (macrophages); panels I L show immunofluorescence staining for CD11c (dendritic cells). Panels A, E, and I are skin sections from 12-week diet-fed SKO mice; panels B, F, and J are skin sections from 6-week diet-fed DKO significant reduction in lupus-like mice; panels C, G, and K are skin sections from 12-week diet-fed DKO mice; panels D, H, and L are skin sections manifestations in mice (63). Thus, from 12-week diet-fed DKO mice treated for 6 weeks with apoa-i. Sections shown are representative of at least we posed the following question. four sections per animal with at least 4 6 different animals per genotype and treatment group. Could treatment with human lipidfree apoa-i reverse inflammation Taken together, these results suggest that treatment with and autoimmunity in DKO mice? Given that cholesterol accuhuman apoa-i reduced inflammation within the skin and LNs, mulation in DKO mice begins as early as 4 weeks on the diet (8, 9), we chose to start apoa-i injections after mice had been on possibly through an increased Treg response. The importance of Tregs in modulating T cell responses is of the diet for 6 weeks, a time point where the cascade of inflamgreat significance because the immune system is complex, with mation and cholesterol accumulation has already begun. As multiple levels of regulation in place to prevent reaction against expected, injection of human apoa-i resulted in the formation self. Tregs maintain peripheral self-tolerance by suppressing of HDL. With HDL apoa-i injections, male DKO mice exhibited reactivation of T cells (28). In addition, Tregs can act on dendritic cells, macrophages, and B cells by inducing apoptosis or by duced infiltrates and inflammation in skin and LNs, including a inhibiting their function (29). Tregs exert their inhibitory decrease in LN-activated T cells. These effects have not been effects by either a contact-dependent process or by secreting demonstrated in female diet-fed DKO mice. We speculate that anti-inflammatory cytokines such as IL-10 and TGF- (29 31). this was due to both the anti-inflammatory properties of HDL Although Tregs have the ability to suppress other cells, it is apoa-i and the restoration of cellular cholesterol efflux. These known that under chronic inflammatory conditions both effec- beneficial effects may be due in part to direct effects of apoa-i tor cells and antigen-presenting cells can become resistant to on cellular function as apoa-i has been shown to inhibit the Treg suppression and produce cytokines that inhibit Treg func- contact-mediated activation of monocytes by stimulated T cells JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 285 NUMBER 46 NOVEMBER 12, 2010
10 (46, 47). ApoA-I of HDL has been shown to reduce the monocyte inflammatory response (48). Interestingly, when ABCA1 was blocked, the beneficial effect of apoa-i was also blocked, suggesting that cholesterol efflux is essential for this mechanism (48). Thus, cholesterol efflux to apoa-i plays an important role in maintaining both cholesterol and immune system homeostasis. With cholesterol efflux restored in DKO A-I mice, cholesterol along with macrophage and DC cell infiltrates were removed from the skin, resulting in an overall reversal of inflammation. This is significant given that skin cholesterol accumulation can prove to be fatal for DKO mice (8, 9). We speculate that cholesterol efflux and the presence of apoa-i reduced cellular activation and inflammation in the skin, allowing for this restoration of skin structure. Importantly, two potentially inflammatory cell types, macrophages and DCs, were reduced in the skin. The decrease in DCs and macrophages in the skin was accompanied by a trend toward increases in both of these cell populations in the LNs, suggesting that these cells may have migrated from the skin to the LNs. This would agree with results from previous studies that indicated that HDL restored migration of DCs from the skin to LNs in hypercholesterolemic mice (49). In hypercholesterolemic apoe / mice, the DCs that are in the skin are activated, and their inability to migrate back to the LNs results in poor immunologic priming and contributes to local inflammation in the skin (49). It is possible that impaired migration of activated DCs from the periphery may aid in exacerbating memory responses to the periphery (49). By helping maintain normal DC migration, HDL supports a healthy protective immune response. Following treatment with apoa-i, the total cholesterol in LNs was reduced compared with DKO mice. This reduction in cholesterol is significant given that an environment with increased cholesterol can lead to increased T cell proliferation (50). Consistent with this idea, a reduction in the total LN cell number was seen in DKO A-I mice compared with DKO mice; however, this was not different from 6-week diet-fed DKO. This suggests that apoa-i treatment did not reverse the cellular accumulation in LNs but rather served to arrest the accumulation and proliferation. It is also possible, however, that the LN cells are involved in cholesterol removal from the skin, with lymphocytes constantly moving from the skin to the LNs, and that the number would be further reduced if the treatment period had been extended to the point where the skin cholesterol accumulation was completely reversed. Nevertheless, the reduction in cells, especially activated T cells, in the LNs demonstrates an important effect of apoa-i treatment on the LNs, where immune responses are stimulated. Tregs are an important component of the immune response, acting to maintain self-tolerance. The absence of or defects in Treg can lead to severe autoimmune disorders (29, 33 35, 51). Despite the autoimmune phenotype in diet-fed DKO mice, Tregs were increased in LNs. This is similar to findings from previous studies in patients with rheumatoid arthritis, where Tregs were increased in synovial fluid of inflamed joints (52, 53). The increase of Treg in tissue suggests that Tregs are homing to sites of inflammation. The correlation between Treg levels in peripheral blood and disease activity is not clear, as some studies have reported increased Tregs in blood, and others show no difference or decreased Tregs compared with healthy patients (33, 54 57). Thus, the level of circulating Treg does not always reflect the levels at the site of inflammation because Treg are typically increased at sites of inflammation (33). When Tregs are increased at sites of inflammation, why does the autoimmunity still exist? Studies suggest that the suppressive activity of Treg may be maintained but that Teffs or chronically activated antigen-presenting cells in some autoimmune models may be able to resist this suppression (29, 32, 33, 58 60). Both the MAPK and NF B pathways have been implicated in the chronic activation of antigen-presenting cells (29). Thus, the MAPK pathway, which is affected in cholesterolloaded T cells from ABCG1 / mice (50), may also play a role in the ability of cells to overcome suppression by Treg. In addition, the cytokine environment may have an effect on the ability of Teff to overcome suppression by Treg, and resistance to Treg suppression by Teff typically occurs in the setting of chronic inflammation (29, 32, 33). Although Tregs produce anti-inflammatory cytokines that can act to suppress Teff, Teffs produce inflammatory cytokines that can render Treg ineffective. Thus, it is important to maintain a balance between Treg and Teff. Although the increase in Treg in DKO mice may seem paradoxical considering the autoimmune phenotype, it may be that the function of LN Treg in DKO mice is impaired or that the Teffs are simply more effective at overcoming suppression. We have previously shown increased proliferation in CD4 cells in DKO mice. The increase in LN Treg (which are CD4 )indko mice may be a direct result of increased CD4 cell proliferation. In other words, Treg may be proliferating along with other CD4 cells. It appears, however, that the Tregs are not proliferating to the same extent as other CD4 cells because the ratio of Treg/Teff in DKO mice is reduced compared with both SKO and DKO A-I. Nevertheless, treatment with apoa-i reduces inflammation in DKO mice, resulting in an increased LN Treg population. In this case, T cell activation is also reduced, suggesting that the Treg function is improved or that Teff cells are less resistant to Treg suppression. Overall, the ratio of Treg/ Teff is increased in DKO A-I mice compared with diet-fed mice. In DKO A-I mice, apoa-i reduces inflammation, improving the ability of Treg to respond to Teff. In this case, the increased Treg/Teff ratio may be a result of selective proliferation of Treg. In other words, Tregs are now proliferating in increased proportion compared with other CD4 cells. Taken together, these data demonstrate that DKO mice have a defective Treg response caused by impaired Treg function or by improved ability of Teff to resist suppression and that the reduction of systemic inflammation in DKO A-I mice allows for an improved Treg response. Interestingly, studies have suggested that Treg can prime DCs in sites of inflammation, leading to a reduction in co-stimulatory signaling with T cells (61, 62). These DCs gain the ability to migrate to secondary lymphoid organs where they present self-antigen to Teff. The reduction in co-stimulatory signaling results in reduced T cell activation (29). This is an interesting point of reference considering the trend toward increased DCs in the LNs. It is possible that Tregs are also present in increased NOVEMBER 12, 2010 VOLUME 285 NUMBER 46 JOURNAL OF BIOLOGICAL CHEMISTRY 36167
Blocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD-
Supplementary Methods Blocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD- L1 (10F.9G2, rat IgG2b, k), and PD-L2 (3.2, mouse IgG1) have been described (24). Anti-CTLA-4 (clone
More informationSupplemental Table I.
Supplemental Table I Male / Mean ± SEM n Mean ± SEM n Body weight, g 29.2±0.4 17 29.7±0.5 17 Total cholesterol, mg/dl 534.0±30.8 17 561.6±26.1 17 HDL-cholesterol, mg/dl 9.6±0.8 17 10.1±0.7 17 Triglycerides,
More informationIn vitro human regulatory T cell expansion
- 1 - Human CD4 + CD25 + regulatory T cell isolation, Workflow in vitro expansion and analysis In vitro human regulatory T cell expansion Introduction Regulatory T (Treg) cells are a subpopulation of T
More informationHuman LDL Receptor / LDLR ELISA Pair Set
Human LDL Receptor / LDLR ELISA Pair Set Catalog Number : SEK10231 To achieve the best assay results, this manual must be read carefully before using this product and the assay is run as summarized in
More informationSupplementary Fig. 1 p38 MAPK negatively regulates DC differentiation. (a) Western blot analysis of p38 isoform expression in BM cells, immature DCs
Supplementary Fig. 1 p38 MAPK negatively regulates DC differentiation. (a) Western blot analysis of p38 isoform expression in BM cells, immature DCs (idcs) and mature DCs (mdcs). A myeloma cell line expressing
More informationIn vitro human regulatory T cell expansion
- 1 - Human CD4 + CD25 + CD127 dim/- regulatory T cell Workflow isolation, in vitro expansion and analysis In vitro human regulatory T cell expansion Introduction Regulatory T (Treg) cells are a subpopulation
More informationSUPPLEMENTARY INFORMATION
doi:1.138/nature1554 a TNF-α + in CD4 + cells [%] 1 GF SPF 6 b IL-1 + in CD4 + cells [%] 5 4 3 2 1 Supplementary Figure 1. Effect of microbiota on cytokine profiles of T cells in GALT. Frequencies of TNF-α
More informationSupplemental Material. Results
Supplemental Material Results Fractionation of mouse plasma by high-resolution SEC. APOA1 eluted as a single major peak in fractions 16 of plasma (the apparent size of mature, lipidated HDL) when it was
More informationRapid antigen-specific T cell enrichment (Rapid ARTE)
Direct ex vivo characterization of human antigen-specific CD154+CD4+ T cell Rapid antigen-specific T cell enrichment (Rapid ARTE) Introduction Workflow Antigen (ag)-specific T cells play a central role
More informationThe toll-like receptor 4 ligands Mrp8 and Mrp14 play a critical role in the development of autoreactive CD8 + T cells
1 SUPPLEMENTARY INFORMATION The toll-like receptor 4 ligands Mrp8 and Mrp14 play a critical role in the development of autoreactive CD8 + T cells Karin Loser 1,2,6, Thomas Vogl 2,3, Maik Voskort 1, Aloys
More informationCell isolation. Spleen and lymph nodes (axillary, inguinal) were removed from mice
Supplementary Methods: Cell isolation. Spleen and lymph nodes (axillary, inguinal) were removed from mice and gently meshed in DMEM containing 10% FBS to prepare for single cell suspensions. CD4 + CD25
More informationSupporting Information
Supporting Information Pang et al. 10.1073/pnas.1322009111 SI Materials and Methods ELISAs. These assays were performed as previously described (1). ELISA plates (MaxiSorp Nunc; Thermo Fisher Scientific)
More informationSupplementary Figure 1. Normal T lymphocyte populations in Dapk -/- mice. (a) Normal thymic development in Dapk -/- mice. Thymocytes from WT and Dapk
Supplementary Figure 1. Normal T lymphocyte populations in Dapk -/- mice. (a) Normal thymic development in Dapk -/- mice. Thymocytes from WT and Dapk -/- mice were stained for expression of CD4 and CD8.
More informationSUPPLEMENTARY INFORMATION
doi:10.1038/nature10134 Supplementary Figure 1. Anti-inflammatory activity of sfc. a, Autoantibody immune complexes crosslink activating Fc receptors, promoting activation of macrophages, and WWW.NATURE.COM/NATURE
More informationSupplementary Information
Supplementary Information Supplementary Figure 1. CD4 + T cell activation and lack of apoptosis after crosslinking with anti-cd3 + anti-cd28 + anti-cd160. (a) Flow cytometry of anti-cd160 (5D.10A11) binding
More informationSupplementary Figures
Supplementary Figures Supplementary Fig. 1. Surface thiol groups and reduction of activated T cells. (a) Activated CD8 + T-cells have high expression levels of free thiol groups on cell surface proteins.
More informationDirect ex vivo characterization of human antigen-specific CD154 + CD4 + T cells Rapid antigen-reactive T cell enrichment (Rapid ARTE)
Direct ex vivo characterization of human antigen-specific CD154 + CD4 + T cells Rapid antigen-reactive T cell enrichment (Rapid ARTE) Introduction Workflow Antigen (ag)-specific T cells play a central
More informationSipper BK Experimental Animal Co. (Shanghai, China) and bred in a specific. pathogen-free environment. The animal study protocol was approved by the
Supplementary information, Data S1 Materials and Methods Mice, Ad vectors and reagents Female C57BL/6 mice, 8-10 weeks of age, were purchased from Joint Ventures Sipper BK Experimental Animal Co. (Shanghai,
More informationB220 CD4 CD8. Figure 1. Confocal Image of Sensitized HLN. Representative image of a sensitized HLN
B220 CD4 CD8 Natarajan et al., unpublished data Figure 1. Confocal Image of Sensitized HLN. Representative image of a sensitized HLN showing B cell follicles and T cell areas. 20 µm thick. Image of magnification
More informationSUPPLEMENTARY INFORMATION
Supplemental Figure 1. Furin is efficiently deleted in CD4 + and CD8 + T cells. a, Western blot for furin and actin proteins in CD4cre-fur f/f and fur f/f Th1 cells. Wild-type and furin-deficient CD4 +
More informationApolipoprotein AI prevents regulatory to follicular helper T cell switching during atherosclerosis
ARTICLE DOI: 1.138/s41467-18-3493- OPEN Apolipoprotein AI prevents regulatory to follicular helper T cell switching during atherosclerosis Dalia E. Gaddis 1, Lindsey E. Padgett 1, Runpei Wu 1, Chantel
More informationSupplemental Figure 1 ELISA scheme to measure plasma total, mature and furin-cleaved
1 Supplemental Figure Legends Supplemental Figure 1 ELISA scheme to measure plasma total, mature and furin-cleaved PCSK9 concentrations. 4 Plasma mature and furin-cleaved PCSK9s were measured by a sandwich
More informationTSH Receptor Monoclonal Antibody (49) Catalog Number MA3-218 Product data sheet
Website: thermofisher.com Customer Service (US): 1 800 955 6288 ext. 1 Technical Support (US): 1 800 955 6288 ext. 441 TSH Receptor Monoclonal Antibody (49) Catalog Number MA3-218 Product data sheet Details
More informationSUPPLEMENTARY FIGURE 1
SUPPLEMENTARY FIGURE 1 A LN Cell count (1 ) 1 3 1 CD+ 1 1 CDL lo CD hi 1 CD+FoxP3+ 1 1 1 7 3 3 3 % of cells 9 7 7 % of cells CD+ 3 1 % of cells CDL lo CD hi 1 1 % of CD+ cells CD+FoxP3+ 3 1 % of CD+ T
More informationSUPPLEMENTARY METHODS
SUPPLEMENTARY METHODS Histological analysis. Colonic tissues were collected from 5 parts of the middle colon on day 7 after the start of DSS treatment, and then were cut into segments, fixed with 4% paraformaldehyde,
More informationNK cell flow cytometric assay In vivo DC viability and migration assay
NK cell flow cytometric assay 6 NK cells were purified, by negative selection with the NK Cell Isolation Kit (Miltenyi iotec), from spleen and lymph nodes of 6 RAG1KO mice, injected the day before with
More informationWalter B. Bayubay CLS (ASCP), AMT, MA Ed, CPI
Walter B. Bayubay CLS (ASCP), AMT, MA Ed, CPI Biochemical Analysis (Lipid Panel) Analyte Total Cholesterol Reference Range Patient A < 200 241 LDL-C /= 40 38 Triglycerides
More informationInterferon γ regulates idiopathic pneumonia syndrome, a. Th17 + CD4 + T-cell-mediated GvH disease
Interferon γ regulates idiopathic pneumonia syndrome, a Th17 + CD4 + T-cell-mediated GvH disease Nora Mauermann, Julia Burian, Christophe von Garnier, Stefan Dirnhofer, Davide Germano, Christine Schuett,
More informationLDL/VLDL Purification Kit (Ultracentrifugation Free)
Product Manual LDL/VLDL Purification Kit (Ultracentrifugation Free) Catalog Number STA- 606 10 preps FOR RESEARCH USE ONLY Not for use in diagnostic procedures Introduction Lipoproteins are submicroscopic
More informationIslet viability assay and Glucose Stimulated Insulin Secretion assay RT-PCR and Western Blot
Islet viability assay and Glucose Stimulated Insulin Secretion assay Islet cell viability was determined by colorimetric (3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide assay using CellTiter
More informationCD14 + S100A9 + Monocytic Myeloid-Derived Suppressor Cells and Their Clinical Relevance in Non-Small Cell Lung Cancer
CD14 + S1A9 + Monocytic Myeloid-Derived Suppressor Cells and Their Clinical Relevance in Non-Small Cell Lung Cancer Po-Hao, Feng M.D., Kang-Yun, Lee, M.D. Ph.D., Ya-Ling Chang, Yao-Fei Chan, Lu- Wei, Kuo,Ting-Yu
More informationCHAPTER 4 IMMUNOLOGICAL TECHNIQUES
CHAPTER 4 IMMUNOLOGICAL TECHNIQUES Nitroblue Tetrazolium Chloride (NBT) Reduction test NBT reduction test was evaluated by employing the method described by Hudson and Hay,1989 based upon principle that
More informationSupporting Information
Supporting Information Desnues et al. 10.1073/pnas.1314121111 SI Materials and Methods Mice. Toll-like receptor (TLR)8 / and TLR9 / mice were generated as described previously (1, 2). TLR9 / mice were
More informationMouse Anti-OVA IgM Antibody Assay Kit
Mouse Anti-OVA IgM Antibody Assay Kit Catalog # 3017 For Research Use Only - Not Human or Therapeutic Use INTRODUCTION Ovalbumin (OVA) is a widely used antigen for inducing allergic reactions in experimental
More informationSUPPORTING INFORMATIONS
SUPPORTING INFORMATIONS Mice MT/ret RetCD3ε KO α-cd25 treated MT/ret Age 1 month 3 mnths 6 months 1 month 3 months 6 months 1 month 3 months 6 months 2/87 Survival 87/87 incidence of 17/87 1 ary tumor
More informationSupplementary Figure 1. Efficient DC depletion in CD11c.DOG transgenic mice
Supplementary Figure 1. Efficient DC depletion in CD11c.DOG transgenic mice (a) CD11c.DOG transgenic mice (tg) were treated with 8 ng/g body weight (b.w.) diphtheria toxin (DT) i.p. on day -1 and every
More informationSupplementary Figure 1 Lymphocytes can be tracked for at least 4 weeks after
Supplementary Figure 1 Lymphocytes can be tracked for at least 4 weeks after photoconversion by using H2B-Dendra2. 4-5 PPs of H2B-Dendra2 BM chimeras were photoconverted and analyzed 7 days (upper panel)
More informationSupplementary Figure S1. Flow cytometric analysis of the expression of Thy1 in NH cells. Flow cytometric analysis of the expression of T1/ST2 and
Supplementary Figure S1. Flow cytometric analysis of the expression of Thy1 in NH cells. Flow cytometric analysis of the expression of T1/ST2 and Thy1 in NH cells derived from the lungs of naïve mice.
More informationSupplemental Information. T Cells Enhance Autoimmunity by Restraining Regulatory T Cell Responses via an Interleukin-23-Dependent Mechanism
Immunity, Volume 33 Supplemental Information T Cells Enhance Autoimmunity by Restraining Regulatory T Cell Responses via an Interleukin-23-Dependent Mechanism Franziska Petermann, Veit Rothhammer, Malte
More informationSupplementary Figure 1. Characterization of basophils after reconstitution of SCID mice
Supplementary figure legends Supplementary Figure 1. Characterization of after reconstitution of SCID mice with CD4 + CD62L + T cells. (A-C) SCID mice (n = 6 / group) were reconstituted with 2 x 1 6 CD4
More informationThe New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk
The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing
More informationFigure S1. Generation of inducible PTEN deficient mice and the BMMCs (A) B6.129 Pten loxp/loxp mice were mated with B6.
Figure S1. Generation of inducible PTEN deficient mice and the BMMCs (A) B6.129 Pten loxp/loxp mice were mated with B6.129-Gt(ROSA)26Sor tm1(cre/ert2)tyj /J mice. To induce deletion of the Pten locus,
More informationSupplementary Data 1. Alanine substitutions and position variants of APNCYGNIPL. Applied in
Supplementary Data 1. Alanine substitutions and position variants of APNCYGNIPL. Applied in Supplementary Fig. 2 Substitution Sequence Position variant Sequence original APNCYGNIPL original APNCYGNIPL
More informationSupplemental Information
Electronic Supplementary Material (ESI) for Food & Function. This journal is The Royal Society of Chemistry 2016 Supplemental Information Supplementary Materials and Methods Materials Assay kits of total
More informationIn vitro human regulatory T cell suppression assay
Human CD4 + CD25 + regulatory T cell isolation, in vitro suppression assay and analysis In vitro human regulatory T cell suppression assay Introduction Regulatory T (Treg) cells are a subpopulation of
More informationProtocol for Gene Transfection & Western Blotting
The schedule and the manual of basic techniques for cell culture Advanced Protocol for Gene Transfection & Western Blotting Schedule Day 1 26/07/2008 Transfection Day 3 28/07/2008 Cell lysis Immunoprecipitation
More informationHuman Apolipoprotein A1 EIA Kit
A helping hand for your research Product Manual Human Apolipoprotein A1 EIA Kit Catalog Number: 83901 96 assays 1 Table of Content Product Description 3 Assay Principle 3 Kit Components 3 Storage 4 Reagent
More informationSupporting Information
Supporting Information Valkenburg et al. 10.1073/pnas.1403684111 SI Materials and Methods ELISA and Microneutralization. Sera were treated with Receptor Destroying Enzyme II (RDE II, Accurate) before ELISA
More informationSummary and concluding remarks
Summary and concluding remarks This thesis is focused on the role and interaction of different cholesterol and phospholipid transporters. Cholesterol homeostasis is accomplished via a tightly regulated
More informationNeutrophils contribute to fracture healing by synthesizing fibronectin+ extracellular matrix rapidly after injury
Neutrophils contribute to fracture healing by synthesizing fibronectin+ extracellular matrix rapidly after injury Bastian OW, Koenderman L, Alblas J, Leenen LPH, Blokhuis TJ. Neutrophils contribute to
More informationLecithin Cholesterol Acyltransferase (LCAT) ELISA Kit
Product Manual Lecithin Cholesterol Acyltransferase (LCAT) ELISA Kit Catalog Number STA-616 96 assays FOR RESEARCH USE ONLY Not for use in diagnostic procedures Introduction Cholesterol is a lipid sterol
More informationAutoimmunity. Autoimmunity arises because of defects in central or peripheral tolerance of lymphocytes to selfantigens
Autoimmunity Autoimmunity arises because of defects in central or peripheral tolerance of lymphocytes to selfantigens Autoimmune disease can be caused to primary defects in B cells, T cells and possibly
More informationSupplementary Information:
Supplementary Information: Follicular regulatory T cells with Bcl6 expression suppress germinal center reactions by Yeonseok Chung, Shinya Tanaka, Fuliang Chu, Roza Nurieva, Gustavo J. Martinez, Seema
More informationSUPPLEMENTAL MATERIAL. Number of patients 14
SUPPLEMENTAL MATERIAL Supplemental Table 1 Number of patients 14 Age, years 54.9 ± 10.0 Female gender, n (%) 6 (42.9) Diabetes, n (%) 2 (14.3) History of hypertension, n (%) 5 (35.7) Ever smoker, n (%)
More informationAlessandra Franco, M.D., Ph.D. UCSD School of Medicine Department of Pediatrics Division of Allergy, Immunology and Rheumatology
Natural regulatory T cells recognize the heavy constant region (Fc) of immunoglobulins: a novel mechanism for IVIG immunotherapy in Pediatric Immune-mediated diseases Alessandra Franco, M.D., Ph.D. UCSD
More informationDepleting Lipoproteins from Serum
Depleting Lipoproteins from Serum Kathy K. Foxx Kalen Biomedical LLC President For decades, fetal bovine serum (FBS) has been used as a supplement for cell-culture media, providing the growth factors that
More informationPBMC from each patient were suspended in AIM V medium (Invitrogen) with 5% human
Anti-CD19-CAR transduced T-cell preparation PBMC from each patient were suspended in AIM V medium (Invitrogen) with 5% human AB serum (Gemini) and 300 international units/ml IL-2 (Novartis). T cell proliferation
More informationHuman Immunodeficiency Virus Type-1 Myeloid Derived Suppressor Cells Inhibit Cytomegalovirus Inflammation through Interleukin-27 and B7-H4
Human Immunodeficiency Virus Type-1 Myeloid Derived Suppressor Cells Inhibit Cytomegalovirus Inflammation through Interleukin-27 and B7-H4 Ankita Garg, Rodney Trout and Stephen A. Spector,,* Department
More informationLipid (Oil Red O) staining Kit
Lipid (Oil Red O) staining Kit Catalog Number KA4541 1 Kit Version: 02 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Background... 3 General Information... 4 Materials
More informationLIST OF ORGANS FOR HISTOPATHOLOGICAL ANALYSIS:!! Neural!!!!!!Respiratory:! Brain : Cerebrum,!!! Lungs and trachea! Olfactory, Cerebellum!!!!Other:!
LIST OF ORGANS FOR HISTOPATHOLOGICAL ANALYSIS:!! Neural!!!!!!Respiratory:! Brain : Cerebrum,!!! Lungs and trachea! Olfactory, Cerebellum!!!!Other:! Spinal cord and peripheral nerves! Eyes, Inner ear, nasal
More informationDetailed step-by-step operating procedures for NK cell and CTL degranulation assays
Supplemental methods Detailed step-by-step operating procedures for NK cell and CTL degranulation assays Materials PBMC isolated from patients, relatives and healthy donors as control K562 cells (ATCC,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Nair S, Branagan AR, Liu J, Boddupalli CS, Mistry PK, Dhodapkar
More informationEvaluation of directed and random motility in microslides Assessment of leukocyte adhesion in flow chambers
Evaluation of directed and random motility in microslides Motility experiments in IBIDI microslides, image acquisition and processing were performed as described. PMN, which ended up in an angle < 180
More informationInstructions for Use. APO-AB Annexin V-Biotin Apoptosis Detection Kit 100 tests
3URGXFW,QIRUPDWLRQ Sigma TACS Annexin V Apoptosis Detection Kits Instructions for Use APO-AB Annexin V-Biotin Apoptosis Detection Kit 100 tests For Research Use Only. Not for use in diagnostic procedures.
More informationSupplemental Figure 1. Signature gene expression in in vitro differentiated Th0, Th1, Th2, Th17 and Treg cells. (A) Naïve CD4 + T cells were cultured
Supplemental Figure 1. Signature gene expression in in vitro differentiated Th0, Th1, Th2, Th17 and Treg cells. (A) Naïve CD4 + T cells were cultured under Th0, Th1, Th2, Th17, and Treg conditions. mrna
More informationSUPPLEMENTARY INFORMATION
Complete but curtailed T-cell response to very-low-affinity antigen Dietmar Zehn, Sarah Y. Lee & Michael J. Bevan Supp. Fig. 1: TCR chain usage among endogenous K b /Ova reactive T cells. C57BL/6 mice
More informationMATERIALS AND METHODS. Neutralizing antibodies specific to mouse Dll1, Dll4, J1 and J2 were prepared as described. 1,2 All
MATERIALS AND METHODS Antibodies (Abs), flow cytometry analysis and cell lines Neutralizing antibodies specific to mouse Dll1, Dll4, J1 and J2 were prepared as described. 1,2 All other antibodies used
More informationVEGFR2-Mediated Vascular Dilation as a Mechanism of VEGF-Induced Anemia and Bone Marrow Cell Mobilization
Cell Reports, Volume 9 Supplemental Information VEGFR2-Mediated Vascular Dilation as a Mechanism of VEGF-Induced Anemia and Bone Marrow Cell Mobilization Sharon Lim, Yin Zhang, Danfang Zhang, Fang Chen,
More informationHuman LDL ELISA Kit. Innovative Research, Inc.
Human LDL ELISA Kit Catalog No: IRKTAH2582 Lot No: SAMPLE INTRODUCTION Human low-density lipoprotein (LDL) transports cholesterol from the liver to tissues where it is incorporated into cell membranes.
More information1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones?
1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones? 3How are dietary lipids transported? 4How lipids synthesized in the liver are transported? 5 Lipoprotien
More informationSupplementary Figures
Inhibition of Pulmonary Anti Bacterial Defense by IFN γ During Recovery from Influenza Infection By Keer Sun and Dennis W. Metzger Supplementary Figures d a Ly6G Percentage survival f 1 75 5 1 25 1 5 1
More informationHuman Immunodeficiency Virus type 1 (HIV-1) p24 / Capsid Protein p24 ELISA Pair Set
Human Immunodeficiency Virus type 1 (HIV-1) p24 / Capsid Protein p24 ELISA Pair Set Catalog Number : SEK11695 To achieve the best assay results, this manual must be read carefully before using this product
More informationChemical Chaperones Mitigate Experimental Asthma By Attenuating Endoplasmic
Chemical Chaperones Mitigate Experimental Asthma By Attenuating Endoplasmic Reticulum Stress Lokesh Makhija, BE, Veda Krishnan, MSc, Rakhshinda Rehman, MTech, Samarpana Chakraborty, MSc, Shuvadeep Maity,
More informationPotential Rebalancing of the Immune System by Anti-CD52 Therapy
Potential Rebalancing of the Immune System by Anti-CD52 Therapy Johanne Kaplan, PhD VP Neuroimmunology Research Genzyme March 26, 2013 RESTRICTED USE SEE TRAINING MEMO 2011 DO Genzyme NOT 1COPY Corporation
More informationBone marrow-derived mesenchymal stem cells improve diabetes-induced cognitive impairment by
Nakano et al. Supplementary information 1. Supplementary Figure 2. Methods 3. References Bone marrow-derived mesenchymal stem cells improve diabetes-induced cognitive impairment by exosome transfer into
More informationJournal of the American College of Cardiology Vol. 50, No. 24, by the American College of Cardiology Foundation ISSN /07/$32.
Journal of the American College of Cardiology Vol. 50, No. 24, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.07.081
More informationHDL Purification Kit (Ultracentrifugation Free)
Product Manual HDL Purification Kit (Ultracentrifugation Free) Catalog Number STA- 607 10 preps FOR RESEARCH USE ONLY Not for use in diagnostic procedures Introduction Lipoproteins are submicroscopic particles
More informationOptimizing Intracellular Flow Cytometry:
Optimizing Intracellular Flow Cytometry: Simultaneous Detection of Cytokines and Transcription Factors An encore presentation by Jurg Rohrer, PhD, BD Biosciences 10.26.10 Outline Introduction Cytokines
More informationHua Tang, Weiping Cao, Sudhir Pai Kasturi, Rajesh Ravindran, Helder I Nakaya, Kousik
SUPPLEMENTARY FIGURES 1-19 T H 2 response to cysteine-proteases requires dendritic cell-basophil cooperation via ROS mediated signaling Hua Tang, Weiping Cao, Sudhir Pai Kasturi, Rajesh Ravindran, Helder
More informationSupplemental Information. Human CD1c + Dendritic Cells Drive. the Differentiation of CD103 + CD8 + Mucosal Effector T Cells via the Cytokine TGF-
Immunity, Volume 38 Supplemental Information Human CD1c + Dendritic Cells Drive the Differentiation of CD103 + CD8 + Mucosal Effector T Cells via the Cytokine TGF- Chun I. Yu Christian Becker Yuanyuan
More informationApolipoprotein A1 (Apo A1) ELISA
Package Insert Apolipoprotein A1 (Apo A1) ELISA 1 x 96 Wells For Research Use Only (RUO). Not for use in clinical, diagnostic or therapeutic procedures. v. 1.0 Eagle Biosciences, Inc. 20A Northwest Blvd.,
More informationHuman Immunodeficiency Virus type 1 (HIV-1) gp120 / Glycoprotein 120 ELISA Pair Set
Human Immunodeficiency Virus type 1 (HIV-1) gp120 / Glycoprotein 120 ELISA Pair Set Catalog Number : SEK11233 To achieve the best assay results, this manual must be read carefully before using this product
More informationOptimizing Intracellular Flow Cytometry:
Optimizing Intracellular Flow Cytometry: Simultaneous Detection of Cytokines and Transcription Factors Presented by Jurg Rohrer, PhD, BD Biosciences 23-10780-00 Outline Introduction Cytokines Transcription
More informationSupplementary Figure S I: Effects of D4F on body weight and serum lipids in apoe -/- mice.
Supplementary Figures: Supplementary Figure S I: Effects of D4F on body weight and serum lipids in apoe -/- mice. Male apoe -/- mice were fed a high-fat diet for 8 weeks, and given PBS (model group) or
More informationSupplementary Figure 1. IL-12 serum levels and frequency of subsets in FL patients. (A) IL-12
1 Supplementary Data Figure legends Supplementary Figure 1. IL-12 serum levels and frequency of subsets in FL patients. (A) IL-12 serum levels measured by multiplex ELISA (Luminex) in FL patients before
More informationPrimary Adult Naïve CD4+ CD45RA+ Cells. Prepared by: David Randolph at University of Alabama, Birmingham
Primary Adult Naïve CD4+ CD45RA+ Cells Prepared by: David Randolph (drdrdr@uab.edu) at University of Alabama, Birmingham Goal: To obtain large numbers of highly pure primary CD4+ CD45RO- CD25- cells from
More informationSUPPLEMENTARY INFORMATION
Supplementary Figures Supplementary Figure S1. Binding of full-length OGT and deletion mutants to PIP strips (Echelon Biosciences). Supplementary Figure S2. Binding of the OGT (919-1036) fragments with
More informationAPOB (Human) ELISA Kit
APOB (Human) ELISA Kit Catalog Number KA4330 96 assays Version: 01 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Background... 3 Principle of the Assay...
More informationW/T Itgam -/- F4/80 CD115. F4/80 hi CD115 + F4/80 + CD115 +
F4/8 % in the peritoneal lavage 6 4 2 p=.15 n.s p=.76 CD115 F4/8 hi CD115 + F4/8 + CD115 + F4/8 hi CD115 + F4/8 + CD115 + MHCII MHCII Supplementary Figure S1. CD11b deficiency affects the cellular responses
More informationHIV-1 p24 ELISA Pair Set Cat#: orb54951 (ELISA Manual)
HIV-1 p24 ELISA Pair Set Cat#: orb54951 (ELISA Manual) BACKGROUND Human Immunodeficiency Virus ( HIV ) can be divided into two major types, HIV type 1 (HIV-1) and HIV type 2 (HIV-2). HIV-1 is related to
More information2.5. AMPK activity
Supplement Fig. A 3 B phos-ampk 2.5 * Control AICAR AMPK AMPK activity (Absorbance at 45 nm) 2.5.5 Control AICAR Supplement Fig. Effects of AICAR on AMPK activation in macrophages. J774. macrophages were
More informationDeterminants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco
Determinants of Immunogenicity and Tolerance Abul K. Abbas, MD Department of Pathology University of California San Francisco EIP Symposium Feb 2016 Why do some people respond to therapeutic proteins?
More informationHuman Urokinase / PLAU / UPA ELISA Pair Set
Human Urokinase / PLAU / UPA ELISA Pair Set Catalog Number : SEK10815 To achieve the best assay results, this manual must be read carefully before using this product and the assay is run as summarized
More informationHCC1937 is the HCC1937-pcDNA3 cell line, which was derived from a breast cancer with a mutation
SUPPLEMENTARY INFORMATION Materials and Methods Human cell lines and culture conditions HCC1937 is the HCC1937-pcDNA3 cell line, which was derived from a breast cancer with a mutation in exon 20 of BRCA1
More informationONLINE SUPPLEMENT MATERIAL. CD70 limits atherosclerosis and promotes macrophage function.
ONLINE SUPPLEMENT MATERIAL CD7 limits atherosclerosis and promotes macrophage function. Holger Winkels* 1,2, Svenja Meiler* 1,2, Esther Smeets* 2, Dirk Lievens 1, David Engel 3, Charlotte Spitz 1, Christina
More informationB6/COLODR/SPL/11C/83/LAP/#2.006 B6/COLODR/SPL/11C/86/LAP/#2.016 CD11C B6/COLODR/SPL/11C/80/LAP/#2.011 CD11C
CD3-specific antibody-induced immune tolerance and suppression of autoimmune encephalomyelitis involves TGF-β production through phagocytes digesting apoptotic T cells Sylvain Perruche 1,3, Pin Zhang 1,
More informationLeptin deficiency suppresses progression of atherosclerosis in apoe-deficient mice
Leptin deficiency suppresses progression of atherosclerosis in apoe-deficient mice Atherosclerosis, 2007 Chiba T, Shinozaki S, Nakazawa T, et al. Present by Sudaporn Pummoung Apolipoprotein E (apoe( apoe)
More informationSupplemental Figure 1
Supplemental Figure 1 1a 1c PD-1 MFI fold change 6 5 4 3 2 1 IL-1α IL-2 IL-4 IL-6 IL-1 IL-12 IL-13 IL-15 IL-17 IL-18 IL-21 IL-23 IFN-α Mut Human PD-1 promoter SBE-D 5 -GTCTG- -1.2kb SBE-P -CAGAC- -1.kb
More informationMales- Western Diet WT KO Age (wks) Females- Western Diet WT KO Age (wks)
Relative Arv1 mrna Adrenal 33.48 +/- 6.2 Skeletal Muscle 22.4 +/- 4.93 Liver 6.41 +/- 1.48 Heart 5.1 +/- 2.3 Brain 4.98 +/- 2.11 Ovary 4.68 +/- 2.21 Kidney 3.98 +/-.39 Lung 2.15 +/-.6 Inguinal Subcutaneous
More informationNote: During 30 minute incubation; proceed thru appropriate sections below (e.g. sections II, III and V).
LEGEND MAX β Amyloid x 40 LEGEND MAX β Amyloid x 40 ELISA Kit Components and Protocol Kit Components Capture Antibody Coated Plate 1 stripwell plate 1 40 Standard (2) 20μg vial 5X Wash Buffer 125mL Standard
More information